- FieldTrip Ventures is opening the world’s first psilocybin research center at the University of the West Indies.
- More research on magic mushrooms follows mounting evidence of the efficacy of ketamine and MDMA.
- Ronan Levy of FieldTrip believes psychedelics could help treat a wide range of mental health conditions.
When I noticed articles floating around about the opening of the world’s first psilocybin research center, I figured they were from satire websites. Sure, the case for therapeutic psychedelics is growing: ketamine is the first psychedelic to be legally prescribed for depression in America; MAPS is entering phase 3 trials for MDMA for the treatment of PTSD; iboga and ayahausca are used in addiction treatment in other nations. And, of course, Johns Hopkins announced the opening of the first psychedelic research center last month.
But a center focused solely on. . . magic mushrooms?
Thank Toronto-based FieldTrip Ventures for that. Ronan Levy is one of the founders. Having cut his teeth in the Canadian medical marijuana business, I was excited to chat with him about this exciting new project (you can hear our full conversation here). The ’60s might have been the golden era of psychedelic experimentation, but we are entering a new phase of clinical research to discover just how effective they are for treating a range of mental health conditions.
Given the results this far, a new era has begun.
(For the source of this article, and to watch a video associated with it, please visit: https://bigthink.com/mind-brain/psilocybin-research-center/)